Systemic therapy in HCC: lessons from brivanib

David Bolos¹, Richard S Finn²

Affiliations

¹ Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, USA.
² Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, USA. Electronic address: Rfinn@mednet.ucla.edu.

PMID: 24972045
DOI: 10.1016/j.jhep.2014.06.019

Free article

Comment

Systemic therapy in HCC: lessons from brivanib

David Bolos et al. J Hepatol. 2014 Oct.

Free article

. 2014 Oct;61(4):947-50.

doi: 10.1016/j.jhep.2014.06.019. Epub 2014 Jun 24.

Authors

David Bolos¹, Richard S Finn²

Affiliations

¹ Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, USA.
² Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, USA. Electronic address: Rfinn@mednet.ucla.edu.

PMID: 24972045
DOI: 10.1016/j.jhep.2014.06.019

No abstract available

Keywords: Angiogenesis; Brivanib; FGFR; Fibroblast Growth Factor; Hepatocellular carcinoma; Sorafenib; VEGFR; Vascular Endothelial Growth Factor Receptor.

PubMed Disclaimer

Comment on

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Robles-Aviña J, Kudo M, Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL. Johnson PJ, et al. J Clin Oncol. 2013 Oct 1;31(28):3517-24. doi: 10.1200/JCO.2012.48.4410. Epub 2013 Aug 26. J Clin Oncol. 2013. PMID: 23980084 Clinical Trial.
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW. Llovet JM, et al. J Clin Oncol. 2013 Oct 1;31(28):3509-16. doi: 10.1200/JCO.2012.47.3009. Epub 2013 Aug 26. J Clin Oncol. 2013. PMID: 23980090 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Systemic therapy in HCC: lessons from brivanib

Affiliations

Systemic therapy in HCC: lessons from brivanib

Authors

Affiliations

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical